Biotechnology company United Therapeutics (NASDAQ: UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to $781.5 million. Its non-GAAP profit of $5.82 per share was 17.4% below analysts’ consensus estimates.

Is now the time to buy UTHR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attributed the shortfall mainly to seasonality and operational disruptions, including severe winter weather and pharmacy issues that slowed patient starts early in the quarter. CEO Dr. Martine Rothblatt emphasized continued progress in the development pipeline, highlighting successful Phase III trial results for both ralinepag and Tyvaso in major indications. President Michael Benkowitz noted that demand for Tyvaso DPI remains robust, with increased patient referrals and shipments in recent months.

Looking ahead, United Therapeutics expects its upcoming product launches to drive substantial growth, with management projecting that ralinepag and Tyvaso for idiopathic pulmonary fibrosis (IPF) could more than double current revenues by 2027. Dr. Rothblatt described the anticipated impact of these therapies as “generational,” citing strong clinical outcomes and broad addressable patient populations. The company is preparing for supplemental regulatory filings and scaling commercial resources in advance of these launches, while also developing multiple drug-device combinations to address diverse patient needs. Management believes these efforts position the company for sustained double-digit growth in the coming years.

Key Insights from Management’s Remarks

Management attributed the first quarter’s performance to ongoing demand for its PAH franchise, operational disruptions, and significant progress in clinical development. The upcoming launches of ralinepag and expanded Tyvaso indications are expected to be pivotal.

• Tyvaso DPI demand steady: Despite a slow start to the quarter, Tyvaso DPI—a dry powder inhaler version of the company’s leading drug—saw year-over-year prescription growth, with more patients now eligible for higher doses.
• Operational headwinds recognized: Severe winter weather and pharmacy issues temporarily affected new patient starts, but management reported that these challenges have been resolved and underlying demand metrics have returned to pre-disruption levels.
• Strong clinical trial results: The company highlighted positive Phase III data from TETON (for Tyvaso in IPF) and ADVANCE OUTCOMES (for ralinepag in PAH), positioning both programs for near-term regulatory filings and potential expedited approvals.
• Multiple product formulations: United Therapeutics is pursuing a “multiple shots on goal” strategy, developing various drug-device combinations (such as DPI, SMI, and oral formulations) to tailor treatments to individual patient preferences and disease nuances.
• Commercial readiness for launches: Investments in the sales force and market access are underway to support the anticipated launches of ralinepag and Tyvaso in new indications, with management emphasizing preparations to capture large, underserved patient populations in IPF and PAH.

Drivers of Future Performance

United Therapeutics' outlook is anchored on successful product launches, continued clinical trial execution, and a diversified product mix targeting larger patient populations.

• Ralinepag and Tyvaso launches: Management expects new product launches—especially ralinepag for PAH and Tyvaso for IPF—to be the primary drivers of growth, supported by strong clinical data and expanding market opportunities. These launches are projected to more than double the company’s revenue base over the next several years.
• Regulatory and market execution: The company is prioritizing rapid regulatory filings, including a supplemental new drug application for Tyvaso in IPF and an NDA for ralinepag, while working closely with payers and providers to facilitate broad adoption. Management cited ongoing engagement with the FDA and preparation for product launches as critical execution risks.
• Pipeline diversification: Ongoing investment in new formulations (such as RALDPI for inhaled ralinepag, and SMI for treprostinil) and expansion into additional diseases like PH-ILD and PH-COPD are expected to provide further long-term growth opportunities and mitigate reliance on any single product.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely monitor (1) the pace and success of Tyvaso and ralinepag regulatory filings and approvals, (2) execution of product launches into new indications and associated commercial uptake, and (3) progress in developing and scaling new formulations such as RALDPI. Additional signals of execution will include adoption trends among prescribers and payer coverage decisions.

United Therapeutics currently trades at $597, up from $572.20 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.